Acute Mesenteric Ischemia
Conditions
Brief summary
This is a prospective, multicentre observational study screening all adult patients admitted to a participating hospital over a 6-month study period (may be adjusted to 4-8 months according to recruitment) and including all patients with suspicion of or confirmed acute mesenteric ischaemia (AMI). Only admission data and hospital mortality outcome will be collected for patients in whom suspicion of AMI is not confirmed. For patients with confirmed AMI full data collection regarding diagnostics, management and long-term outcome is required. Investigators aim to recruit 40-50 sites with expected median of 10-20 patients with confirmed AMI per site during the study period (naturally depending on the size of the hospital). The start of the study is planned for Spring 2022. The aim of the study is to identify the incidence of AMI and its different forms in adult hospitalized patients, and to describe patient characteristics (demographic, clinical and laboratory) at baseline, applied diagnostics and management, as well as outcomes in patients with AMI. An additional aim is to compare the baseline characteristics and outcomes of patients with confirmed AMI to those of patients with suspected AMI in whom the diagnosis was not confirmed.
Interventions
OTHERNo intervention
No intervention
Sponsors
University of Tartu
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
All patients with suspected AMI
Exclusion criteria
Age \<18 years Consent declined by patient or next of kin Chronic mesenteric ischaemia without an acute event
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of AMI | 6 months | Incidence of AMI in hospitalized adult patients in acute care hospitals |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Proportion of different forms of AMI | 6 months | Proportion of each form of AMI from all AMI cases |
| Time to diagnosis | through study completion, study duration 6 months | Time from symptoms to diagnosis |
| Time to treatment | through study completion, study duration 6 months | Time from diagnosis to treatment |
| 30 days survival of AMI | 30 days after admission/suspicion of AMI/study inclusion | survival of patients with confirmed AMI |
| 1 year survival | 1 year | Survival of patients with AMI 1 year after diagnosis |
| Quality of life score | 1 year | EQ-5D-5L (EuroQoL - European Quality of Life ), 5-25 points, the lower score means better outcome |
| Treatment | through study completion, study duration 6 months | Surgery, endovascular intervention or palliation |
Countries
Estonia, Switzerland
Outcome results
None listed